JPRN-jRCT2080224531已完成3 期
Effect and safety of NN9535 in weight management (NN9536-4382)
ovo Nordisk Pharma Ltd.0 个研究点目标入组 401 人开始时间: 2019年1月29日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 401
研究概览
简要总结
Semaglutide 2.4 mg and semaglutide 1.7 mg were superior to placebo with respect to weight loss (-13.19% vs-9.65% vs -2.12%; ETD Sema 2.4 mg:-11.06% [-12.88; -9.24]95% CI; ETD Sema 1.7 mg: -7.52% [-9.62; -5.43]95% CI), including 5, 10 and 15% weight loss responders and waist circumference "-Semaglutide 2.4 mg and semaglutide 1.7 mg were overall well tolerated and the safety and tolerability profiles were consistent with the GLP-1 RA class in general
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •BMI >= 27.0 kg/m2 with >= 2 weight related comorbidities or BMI >= 35.0 kg/m2 with >= 1 weight related comorbidity
排除标准
- •Severe heart failure, History of pancreatitis, Severe psychological disorder, other
研究者
相似试验
已完成
3 期
Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With ObesityObesityNCT04998136Novo Nordisk A/S150
已完成
3 期
Research Study Looking at How Well Semaglutide Works in People Living With Obesity and PrediabetesObesityNCT05040971Novo Nordisk A/S207
尚未招募
3 期
Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)ObesityNCT06616961Popular Medical College Hospital480
尚未招募
3 期
A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®ObesityNCT06633783Hangzhou Jiuyuan Gene Engineering Co. Ltd.,370
已完成
3 期
Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy RangeOverweightObesityNCT05564117Novo Nordisk A/S307